Münz Christian
Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland.
Nat Rev Microbiol. 2025 Apr 25. doi: 10.1038/s41579-025-01181-y.
Sixty years after its discovery as the first human tumour virus, Epstein-Barr virus (EBV)-specific therapies and vaccines have entered clinical trials. These might not only be applicable for EBV-associated malignancies, where the virus was originally discovered, but also to immunopathologies, including the autoimmune disease multiple sclerosis, which might be triggered in susceptible individuals by primary EBV infection. This Review discusses the surprisingly large spectrum of diseases that EBV seems to cause, as well as which of these might be treated by the therapeutic approaches that are currently being developed or are already clinically applied. New pharmacological inhibitors, antibody therapies, adoptive T cell therapies and active vaccinations are beginning to offer possibilities to target the various EBV infection programmes that are associated with different diseases. These novel developments might allow us to specifically target EBV rather than its host cells in virus-associated pathologies.
在被发现为第一种人类肿瘤病毒60年后，针对爱泼斯坦-巴尔病毒（EBV）的疗法和疫苗已进入临床试验阶段。这些疗法和疫苗不仅可能适用于最初发现该病毒的EBV相关恶性肿瘤，还可能适用于免疫病理学疾病，包括自身免疫性疾病多发性硬化症，该病可能由原发性EBV感染在易感个体中引发。本综述讨论了EBV似乎会引发的一系列令人惊讶的广泛疾病，以及目前正在研发或已临床应用的治疗方法可能针对其中哪些疾病。新的药理学抑制剂、抗体疗法、过继性T细胞疗法和主动疫苗接种开始为针对与不同疾病相关的各种EBV感染程序提供了可能。这些新进展或许能让我们在病毒相关疾病中特异性地靶向EBV而非其宿主细胞。
